NovoCare Pharmacy (Wegovy) vs. Oak Longevity: prices, fine print, and the honest verdict

Tirzepatide pricing

NovoCare Pharmacy (Wegovy) routes patients to brand-name medication (Wegovy injectable (all doses $349), Wegovy HD 7.2 mg ($399), Wegovy oral tablets ($149 intro)): your medication cost is the manufacturer's self-pay rate (Zepbound $299–$449, Wegovy $349) or an insurance copay, plus any program fee. Oak Longevity does not offer tirzepatide.

Semaglutide pricing

On semaglutide, Oak Longevity wins at $133 versus $349 all-in — $216/mo apart. NovoCare Pharmacy (Wegovy): Semaglutide runs $349 a month all-in at the standing rate ($199 on intro/plan terms). Oak Longevity: Semaglutide runs $133 a month all-in.

Different products, not just different prices

NovoCare Pharmacy (Wegovy) fulfills the FDA-approved product — reviewed manufacturing, verified identity and sterility, stable legal status — while Oak Longevity sells compounded medication: pharmacy-prepared, not FDA-reviewed, and operating under the narrower post-shortage pathways our legal guide tracks. The compounded discount is partly a risk premium; whether it's worth taking depends on the pharmacy behind it and your tolerance for regulatory turbulence.

Transparency

NovoCare Pharmacy (Wegovy): Source-verified (verified 2026-08-09); names its pharmacy — Novo Nordisk direct / retail partners. Oak Longevity: Source-verified (verified 2026-08-08); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

NovoCare Pharmacy (Wegovy): none; no subscription. Oak Longevity: none stated; no subscription.

The semaglutide board

On semaglutide, Oak Longevity prices at $133 against $349 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. NovoCare Pharmacy (Wegovy) bills at manufacturer/insurance rates plus any stated program fee; Oak Longevity publishes no figure to normalize. 4 · Evidence tiered. NovoCare Pharmacy (Wegovy): source-verified, read 2026-08-09; Oak Longevity: source-verified, read 2026-08-08. 5 · Pharmacy weighed. NovoCare Pharmacy (Wegovy) names Novo Nordisk direct / retail partners; Oak Longevity names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

NovoCare Pharmacy (Wegovy): no membership — the medication figure is the billed figure; no subscription; commitment: none. Oak Longevity: no membership — the medication figure is the billed figure; no subscription; commitment: none stated. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

NovoCare Pharmacy (Wegovy) carries source-verified pricing (last read 2026-08-09); pharmacy disclosure is its strong suit — Novo Nordisk direct / retail partners, manufacturer direct. Oak Longevity carries source-verified pricing (last read 2026-08-08); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: NovoCare Pharmacy (Wegovy): shipping included (or retail via savings card); consultation bring your own prescription; prescription required visit model; savings-card pickup at 70,000+ retail pharmacies as the mail-order alternative. Oak Longevity: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick NovoCare Pharmacy (Wegovy) if a named pharmacy is non-negotiable for you; only the FDA-approved product will do. Pick Oak Longevity if the semaglutide line is cheaper here. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Widen the frame one step and the strongest adjacent options are NexLife at $215 (flat, no membership, named pharmacy); Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

This one is a product decision more than a price decision — cheapest-possible compounded versus FDA-approved brand. Both records, with dates and sources, live in the pricing database.